Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Item
http://www.wikidata.org/entity/Q38882332
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaIdelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathwaysCombination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyCopanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
P2860

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Item
http://www.wikidata.org/entity/Q38882332
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy of phosphatidylinosit ...... ic lymphocytic leukemia cells.
@en
type
label
Efficacy of phosphatidylinosit ...... ic lymphocytic leukemia cells.
@en
prefLabel
Efficacy of phosphatidylinosit ...... ic lymphocytic leukemia cells.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Efficacy of phosphatidylinosit ...... ic lymphocytic leukemia cells.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921